<DOC>
	<DOC>NCT00996853</DOC>
	<brief_summary>The focus of this study is to assess the safety of GSK's H1N1 vaccine in real life conditions as soon as the vaccine is used, in a mass vaccination programme, and with a system for rapid generation, communication and evaluation of safety data. This study is a commitment to the European Medicines Agency (EMEA), as part of GlaxoSmithKline Biologicals' (GSK Biologicals') risk management plan for pandemic influenza vaccination.</brief_summary>
	<brief_title>Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom</brief_title>
	<detailed_description>Collaborator: Medicines and Healthcare products Regulatory Agency</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written informed consent, and assent where appropriate, obtained from the subject/from the subject's parent(s)/ Legally Acceptable Representative(s) (LAR). A male or female subject vaccinated with a first dose of GSK Biologicals' H1N1 pandemic influenza vaccine shortly (&lt;24h) before being recruited in the study, and within a GP practice participating in the study and where the subject is registered. Subjects who the Investigator believes that they and/or their parent(s)/LAR can and will comply with the requirements of the protocol Subjects already vaccinated with any other H1N1 pandemic vaccine before study enrolment. Child in care</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>safety</keyword>
	<keyword>Influenza</keyword>
	<keyword>vaccine</keyword>
	<keyword>reactogenicity</keyword>
	<keyword>swine flu</keyword>
</DOC>